Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.
Which stocks are moving on Tuesday? Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Top movers in Tuesday's session Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Reports Q3 2025 Earnings Miss on Revenue, Beat on EPS Vanda Pharma's Q3 2025 results show a revenue miss but a smaller-than-expected loss. The stock fell as strong Fanapt sales growth was offset by investor focus on the top-line shortfall.
Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda Pharmaceuticals.
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas.
Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals” The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process.
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today A regulator's decision drained the market's enthusiasm for the company.
